Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Yared

Showing results (71-80 of 123) with videos related to

Pageof 13
Sort By:
Transplantation and Cellular Therapy|November 28, 2022
Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant DiseasesLarisa Broglie, Brian D Friend, Saurabh Chhabra, et al.
Haematologica|September 7, 2023
Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cellsYamini K Kathari, Haroon Ahmad, Michael E Kallen, et al.
JAMA Oncology|June 5, 2020
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic TransplantNilanjan Ghosh, Sairah Ahmed, Kwang Woo Ahn, et al.
Nature Communications|July 3, 2025
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myelomaDjordje Atanackovic, Tim Luetkens, Dina Schneider, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2019
Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 DecadesDeepak Kilari, Anita D'Souza, Raphael Fraser, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 7, 2018
Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free SurvivalAmin Alousi, Tao Wang, Michael T Hemmer, et al.
Blood Advances|September 1, 2019
Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1Celalettin Ustun, Soyoung Kim, Min Chen, et al.
The New England Journal of Medicine|November 27, 2024
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Karamjeet S Sandhu, Eleni Tholouli, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 28, 2019
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin LymphomaSairah Ahmed, Jennifer A Kanakry, Kwang W Ahn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 30, 2017
Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34<sup>+</sup> Yields Are LessDavid F Stroncek, Bronwen E Shaw, Brent R Logan, et al.
Pageof 13

Showing results (71-80 of 123) with videos related to

Sort By:
Pageof 13
Transplantation and Cellular Therapy|November 28, 2022
Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant DiseasesLarisa Broglie, Brian D Friend, Saurabh Chhabra, et al.
Haematologica|September 7, 2023
Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cellsYamini K Kathari, Haroon Ahmad, Michael E Kallen, et al.
JAMA Oncology|June 5, 2020
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic TransplantNilanjan Ghosh, Sairah Ahmed, Kwang Woo Ahn, et al.
Nature Communications|July 3, 2025
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myelomaDjordje Atanackovic, Tim Luetkens, Dina Schneider, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2019
Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 DecadesDeepak Kilari, Anita D'Souza, Raphael Fraser, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 7, 2018
Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free SurvivalAmin Alousi, Tao Wang, Michael T Hemmer, et al.
Blood Advances|September 1, 2019
Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1Celalettin Ustun, Soyoung Kim, Min Chen, et al.
The New England Journal of Medicine|November 27, 2024
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Karamjeet S Sandhu, Eleni Tholouli, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 28, 2019
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin LymphomaSairah Ahmed, Jennifer A Kanakry, Kwang W Ahn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 30, 2017
Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34<sup>+</sup> Yields Are LessDavid F Stroncek, Bronwen E Shaw, Brent R Logan, et al.
Pageof 13